Corpus ID: 34655795

CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis.

@article{Baumgart2010CB0105MMXAN,
  title={CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis.},
  author={Daniel C. Baumgart},
  journal={Current opinion in investigational drugs},
  year={2010},
  volume={11 5},
  pages={
          571-6
        }
}
  • D. Baumgart
  • Published 1 May 2010
  • Medicine
  • Current opinion in investigational drugs
CB-01-05-MMX (LMW Heparin MMX), being developed by Cosmo Pharmaceuticals SpA, is a novel oral parnaparin sodium formulation for the potential treatment of ulcerative colitis. At the time of publication, clinical trial data were limited and the mechanism of action had not been elucidated. However, in one phase I and one phase IIb trial in patients with left-sided ulcerative colitis, CB-01-05-MMX had an acceptable safety profile and was not associated with bleeding complications, which is a known… Expand
2 Citations
Characteristics of Hemorheology in Patients with Acute Severe Ulcerative Colitis and the Clinical Study of Rivaroxaban Anticoagulant Therapy
TLDR
Rivaroxaban anticoagulant therapy added to routine treatment was more effective than conventional treatment alone, which significantly improved the blood coagulation status of patients, alleviated clinical symptoms, relieved the endoscopic and histological outcomes, reduced the required hormone dosage and were worthy of clinical promotion. Expand